Smartphone EEG in Bhutan
MASTER-2: An Observational Study Evaluating Cladribine
The MASTER-2 trial is an observational study to evaluate the effectiveness and patient-reported outcomes in people with relapsing forms of multiple sclerosis who are transitioning from ocrelizumab to cladribine. If interested, please contact Dylan Rice, Clinical Research Coordinator, at 617-643-2947 or email@example.com.
Assessment of Portable Magnetic Resonance Imaging
The Neurological Clinical Research Institute is currently recruiting participants with multiple sclerosis. Participants will receive a MRI scan lasting about 25 minutes at the MGH-Charlestown Martinos Center. Participants are paid $80. If interested, please contact Dylan Rice, Clinical Research Coordinator, at 617-643-2947 or firstname.lastname@example.org.Download study flyer
EvolutionRMS: A Phase III Randomized Controlled Study of Evobrutinib to Evaluate Efficacy and Safety
The EvolutionRMS study is looking at a medication called evobrutinib for people with relapsing multiple sclerosis (RMS) with relapses. This investigational medication will be compared to teriflunomide, a medication that is already being used to treat RMS, during a 2-year-long study.
VERISMO: An Observational Study of MS Patients - Now Enrolling
Ocrelizumab has been shown to be an effective treatment option for patients with MS, but the FDA has requested that a study be undertaken to determine the long-term health effects of ocrelizumab.This 10-year-long study will observe 4,000 patients in the US and Germany who have newly started ocrelizumab or another MS disease modifying therapy. Participation in this observational study does not require any special visits to MGH; instead, the research team will follow participants through the electronic medical record for up to 5 years. If you are interested in participating, please contact Dylan Rice at email@example.com or 617-643-2947, or visit the study page on rally.partners.org for further details.
MAMBO: Treating Post-Stroke Disability in Tanzania with Fluoxetine
In the MAMBO (Kiswahili for “Hello”) clinical trial, we tested the safety and tolerability of fluoxetine for post-stroke motor recovery in Tanzania. We also investigated post-stroke dementia in Tanzanian patients. Funded by the National Institutes of Health. The results of the project were reported in the American Journal of Tropical Medicine and Hygiene.
Electronic Pill Bottle Monitoring to Promote Medication Adherence in Multiple Sclerosis
Keeping track of whether you've taken your medications can be difficult, but in diseases like Multiple Sclerosis (MS) taking a medication regularly can have a great impact on the course of the disease. We are undertaking a study to determine if electronic pill bottles can help patients with MS remember to take their oral disease modifying therapies more regularly. Enrollment for this study is now complete. Please contact Dylan Rice (firstname.lastname@example.org or 617-643-2947) if you are interested in hearing more about this project.
Smartphone EEG in Bhutan and Guinea
The group is conducting a clinical study to test the feasibility of using a smartphone-based electroencephalograph (EEG) system to diagnose patients with epilepsy in Bhutan, a small, land-locked country between China and India, and Guinea, a country on the Atlantic coast of Africa bordered by Mali and Sierra Leone. Funded by the Charles Hood Foundation, the Harvard University Asia Center and the National Institutes of Health (NIH).
Resources for the Smartphone EEG project:
- Guinea Epilepsy Survey
- Erica McKenzie's interview with the Living Well with Epilepsy Blog
- NIH RePORTER
- Published results
- BrainCapture Smartphone EEG website
Light Therapy for Fatigue in Multiple Sclerosis
Fatigue is the most commonly reported symptom among people living with MS, and more than a quarter report fatigue as their most disabling symptom. We are conducting a double-blind, placebo-controlled clinical trial to determine whether light therapy can be used as a treatment for MS-related fatigue
Resources for the multiple sclerosis light therapy study:
A Global Atlas of NMO Diagnosis and Treatment Practices
Neuromyelitis optica (NMO) is a demyelinating disease of the optica nerve and spinal cord. Despite recent advances in the treatment and diagnosis of NMO, little is known about the global availability of diagnostic tests and medications for the disease. We surveyed physicians from over 120 different countries on the availability, affordability, and accessibility of a variety of clinical options to diagnose and treat neuromyelitis optica (NMO).
Platelet Signatures in Multiple Sclerosis
Platelet Signatures in Multiple Sclerosis When faced with clinical symptoms of multiple sclerosis (MS), a neurodegenerative condition, patients and physicians can be uncertain of how to proceed. There are multiple diseases that mimic the symptoms of MS; some of them require special treatment and care.
A blood test for MS could allow physicians to more confidently direct the care of their patients; unfortunately, no such blood test currently exists. But there is evidence that platelet RNA signatures may change in MS patients. We are analyzing the blood of MS patients, healthy patients, and patients with MS- mimicking diseases to determine whether there is a platelet-based RNA signature that can help confirm diagnosis of multiple sclerosis.
See complete list of publications on PubMed.
The Global Neurology Research Group would like to thank our funding partners for helping to make our research possible:
- National Institutes of Neurological Disorders and Stroke
- NIH Fogarty International Center
- Canadian Institutes of Health Research
- American Brain Foundation
- The Sumaira Foundation for NMO
- National Multiple Sclerosis Society
- Harvard University Center for AIDS Research
- Grand Challenges Canada
- Charles H. Hood Foundation
- Bill & Melinda Gates Foundation
Support Our Work
Donor support enables Dr. Mateen to reach patients in under-resourced countries and implement care strategies, bringing us closer to improved neurological health for patients around the world.